FindTrial
Sign In

Role of Phalatrikadi Ghanavati in blood disorder

Study on Phalatrikadi Ghanavati as an adjuvant in the management of beejadushtijanya Pandu Thalassemia Major

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/03/024129
Enrollment
30
Registered
2020-03-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D561- Beta thalassemia Health Condition 2: I999- Unspecified disorder of circulatory system Health Condition 3: I999- Unspecified disorder of circulatory system

Interventions

Intervention1: Phalatrikadi Ghanavati: Aamalaki Haritaki Bibhitaki Amrita Vasa Bhunimba Katuki Nimba 100 mg 150 mg 200mg twice a day with lukewarm water Control Intervention1: Iron chelation therapy:

Sponsors

Mahatma Gandhi Ayurved College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children between the age group of 4 to 15 yeatrs Children of both sex

Exclusion criteria

Exclusion criteria: Diagnosed cases like HIV Hepatic failuar requiring blood transfusion at an interval of 15 days

Design outcomes

Primary

MeasureTime frame
Changes in the symtomps of Thalassemia, Daurbalya(Weakness)Aruchi(Anorexia)Udarshoola(Abdominal Pain) Sandhishoola (Joint Pain)Jwar (Fever)Panduta(Jaundice)Pleehavridhi(Spleenomegaly)Yakritvridh (Hepatomegaly, To increase the period between Blood Transfusion To reduce iron overloadTimepoint: 60 days—

Secondary

MeasureTime frame
Quality of life increaseTimepoint: 8 weeks;Quality of Life to Observe changes in hematological and biochemical investigationTimepoint: 8 weeks—

Countries

India

Contacts

Public ContactPavan Morey

Mahatma Gandhi Ayurved College and Hospital and Research center salod (H) Wardha

dr.sriharisharma@gmail.com7776077626

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026